Key Highlights
● ImmunityBio slid sharply on November 9 despite strong Anktiva growth.
● Third-quarter product Revenue was $48.7 million.
● That was up about half from a year earlier.
● Investors appear to have wanted more.
Growth, but not enough
ImmunityBio (NASDAQ:IBRX) slid sharply on Monday, November 9, 2026, after reporting third-quarter product revenue of $48.7 million from its cancer drug Anktiva, according to news reports. That figure was up by about half from a year earlier, a strong growth rate by most standards.
The shares sold off anyway. Early-afternoon and later readings both showed steep declines. Market data did not offer a detailed explanation, noting only that the stock fell despite the growth, which suggests investor expectations had been set higher.
The expectations game
Stock reactions to Earnings often depend less on the raw numbers than on how they compare with what investors anticipated. When a company has a promising product and a loyal investor following, hopes can run ahead of what the Business delivers in any given quarter. Even impressive growth can then disappoint.
That dynamic is common in biotech, where a company's value is often tied to the long-term potential of one or two drugs. When early sales come in below hopes, investors can quickly reassess how large that drug might eventually become.
What Anktiva does
Anktiva is ImmunityBio's approved treatment for a form of bladder cancer, used together with BCG, a long-standing immunotherapy. It is designed to boost the body's immune response against cancer cells. As ImmunityBio's first commercial product, Anktiva is central to the company's story, so its sales trajectory receives close attention from investors.
Bladder cancer is one of the more common cancers, and the non-muscle-invasive form, which stays in the inner lining of the bladder, often comes back after treatment. Patients whose disease no longer responds to standard BCG therapy have limited options, which is the setting where Anktiva has been positioned. That unmet need underpins the long-term sales hopes investors attach to the drug.
A rough day for some biotechs
ImmunityBio was among several drug developers that fell on company news. Ionis Pharmaceuticals (NASDAQ:IONS) plunged after cutting its 2026 forecast for Tryngolza sales, according to market coverage. Faeth Therapeutics (NASDAQ:FTH) tumbled after early endometrial cancer data fell short of investor hopes, and Zura Bio (NASDAQ:ZURA) collapsed after its lead drug missed its main goal in a study. Arrowhead Pharmaceuticals (NASDAQ:ARWR) also dropped, though no company-specific news was found.
There were bright spots too. Vir Biotechnology (NASDAQ:VIR) rose after a late-stage hepatitis Delta trial met its main goal, and Immunovant (NASDAQ:IMVT) gained on positive rheumatoid arthritis data.
A strong market overall
ImmunityBio's slide stood out against a powerful rally. The Nasdaq Composite surged 673.71 points to 25,253.14, its best session since July 30, while the S&P 500 climbed 173.08 points to 7,549.94 and the Russell 2000 rallied 86.71 points to 2,840.81. Falling oil prices, on hopes for a US-Iran peace deal, and a sharp rebound in chip stocks drove the advance, and all 11 S&P 500 sectors finished higher.
Expectations Versus Growth
Investors will focus on whether Anktiva's sales growth can keep pace in coming quarters. Key indicators include the number of treatment centers using the drug, reimbursement trends and any progress in expanding Anktiva into additional types of cancer or patient groups.
Company commentary on Demand and expenses, along with any analyst revisions after the report, could shape sentiment. On the macro side, Tuesday's October Consumer Price Index is the last Inflation report before the Federal Reserve's December 8-9 meeting, where markets widely expect a rate hike. Higher interest rates can weigh on biotech companies that are still working toward sustained profitability.

_11_17_2026_18_52_19_451299.jpg)




Please wait processing your request...